Investor open day and notice of results

20 April 2017

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

Investor open day and notice of results

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM") invites current and potential shareholders to visit its facility in Chichester, West Sussex at 10.30 am on Friday 5 May 2017.

Visitors will have the opportunity to tour the facility including the newly extended probe production line, to see progress on current research and development projects and to talk to senior management about recent developments. The meeting is expected to last approximately two hours.

To reserve a place please email the Company at investorinfo@deltexmedical.com or telephone Leah Chowns on 01243 774 837.

Notice of results

The Company will be announcing its results for the year ended 31 December 2016 on Thursday 27 April 2017, rather than 24 April as previously indicated due to logistical constraints in facilitating final sign-offs of the announcement.

For further information, please contact:-

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.